ABM 2526
Alternative Names: ABM-2526Latest Information Update: 23 Dec 2022
At a glance
- Originator ABM Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action EphA2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 16 Dec 2022 Preclinical trials in Solid tumours in China, USA (unspecified route) (ABM Therapeutics pipeline; December 2022)